fbpx
Sign up to get Fort Worth news delivered every weekday morning.

Posted inPress Release

Nanoscope Therapeutics announces first patient dosed in STARLIGHT Phase 2 clinical trial of MCO-010 Optogenetic

e BEDFORD, TX (July 25, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.“This trial represents the second indication for our vision-restoring […]